echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Anesthesia Topics > PLOS MED: Adding gabapentin to pain relief after opioid use is associated with increased risk of falls!

    PLOS MED: Adding gabapentin to pain relief after opioid use is associated with increased risk of falls!

    • Last Update: 2022-04-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Gabapentinoids are increasingly used to manage chronic noncancer pain (CNCP) in older adults
    .


    When used concomitantly with opioids, gabapentinoids may exacerbate central nervous system (CNS) depression and increase the risk of falls


    Management When used concomitantly with opioids, gabapentinoids may exacerbate central nervous system (CNS) depression and increase the risk of falls


    Researchers conducted a population-based cohort study between 2011-2018 using a 5% national sample of Medicare beneficiaries in the United States
    .


    The study sample included fee-for-charge (FFS) beneficiaries aged ≥65 years with a diagnosis of CNCP and initiation of opioid use


    diagnosis

    Using risk set sampling, each concurrent user was matched with up to 4 opioid-only users on the day of opioid initiation
    .


    Patients were followed from index day to first fall-related injury event, treatment discontinuation or conversion, death, Medicare cancellation, hospitalization or nursing home admission, or study end, as determined using a valid claims-based algorithm


    Ultimately 6733 concurrent users and 27092 matched pure opioid users were identified in cohort 1 and 5709 concurrent users and 22388 matched pure opioid users in cohort 2
    .


    During follow-up, the rate of falls-related injuries per 24.


    Fall-related injuries occurred at a rate of 24.


    In cohort 1, those who used both opioids and gabapentin had a similar risk of fall-related injury as those who used opioids alone (aHR=0.
    97, 95% CI 0.
    71-1.
    34, p=0.
    874), but in cohort 2, Concomitant use had a nearly 70% higher risk of fall-related injury than opioid-only use (aHR=1.
    69, 95% CI 1.
    17-2.
    44, p = 0.
    005)
    .

    In cohort 1, those who used both opioids and gabapentin had a similar risk of fall-related injury as those who used opioids alone (aHR=0.
    97, 95% CI 0.
    71-1.
    34, p=0.
    874), but in cohort 2, Concomitant use had a nearly 70% higher risk of fall-related injury than opioid-only use (aHR=1.
    69, 95% CI 1.
    17-2.
    44, p = 0.
    005)
    .


    In cohort 1, those who used both opioids and gabapentin had a similar risk of fall-related injury as those who used opioids alone (aHR=0.


    Concomitant use of gabapentin and opioids in CNCP older adults did not increase falls-related injuries, but adding gabapentin to existing opioid regimens was associated with an increased risk of falls


    Concurrent use of prescription gabapentinoids with opioids and risk for fall-related injury among older US Medicare beneficiaries with chronic noncancer pain: A population-based cohort study.


    Concurrent use of prescription gabapentinoids with opioids and risk for fall-related injury among older US Medicare beneficiaries with chronic noncancer pain: A population-based cohort study.
    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.